Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Tanzania has been steadily growing over the years, driven by a combination of factors such as increasing prevalence of rheumatoid arthritis, rising awareness about the disease, and the availability of affordable treatment options.
Customer preferences: Patients suffering from rheumatoid arthritis in Tanzania prefer to be treated with a combination of medication and non-pharmacological therapies such as exercise and physical therapy. While there is a preference for conventional disease-modifying antirheumatic drugs (DMARDs), there is also a growing demand for biologic DMARDs due to their efficacy in treating the disease.
Trends in the market: The Anti-Rheumatic Drugs market in Tanzania is witnessing a shift towards biologic DMARDs due to their effectiveness in treating rheumatoid arthritis. This trend is driven by increasing awareness about the disease and the availability of affordable biologic DMARDs. Additionally, the market is also witnessing a rise in the number of local manufacturers of Anti-Rheumatic Drugs, which is expected to drive down the cost of treatment.
Local special circumstances: The healthcare infrastructure in Tanzania is still developing, and there is a shortage of rheumatologists and other healthcare professionals who are trained in treating rheumatoid arthritis. This has led to a delay in diagnosis and treatment, which has resulted in a higher prevalence of the disease. However, the government has taken steps to address this issue by increasing the number of healthcare professionals and investing in healthcare infrastructure.
Underlying macroeconomic factors: Tanzania has a growing economy, which has led to an increase in healthcare spending. Additionally, the government has implemented policies to promote local manufacturing of pharmaceuticals, which has led to a rise in the number of local manufacturers of Anti-Rheumatic Drugs. This has resulted in increased competition and lower prices, making treatment more affordable for patients. However, the market is still heavily reliant on imports, which makes it vulnerable to fluctuations in the global market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
